Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$3.79 - $8.3 $74,443 - $163,028
19,642 Added 31.23%
82,529 $352,000
Q1 2023

May 12, 2023

SELL
$5.89 - $10.52 $16,492 - $29,456
-2,800 Reduced 4.26%
62,887 $430,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $312 - $553
55 Added 0.08%
65,687 $0
Q3 2022

Nov 04, 2022

SELL
$7.17 - $13.87 $3,585 - $6,935
-500 Reduced 0.76%
65,632 $631,000
Q2 2022

Aug 15, 2022

SELL
$5.86 - $13.23 $3,281 - $7,408
-560 Reduced 0.84%
66,132 $479,000
Q1 2022

May 13, 2022

SELL
$10.92 - $16.41 $19,907 - $29,915
-1,823 Reduced 2.66%
66,692 $861,000
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $21,643 - $25,997
-1,369 Reduced 1.96%
68,515 $1.21 Million
Q3 2021

Nov 15, 2021

SELL
$12.68 - $17.79 $53,991 - $75,749
-4,258 Reduced 5.74%
69,884 $1.23 Million
Q2 2021

Aug 16, 2021

SELL
$12.95 - $15.41 $968,711 - $1.15 Million
-74,804 Reduced 50.22%
74,142 $1.03 Million
Q1 2021

May 12, 2021

SELL
$14.42 - $21.39 $1.48 Million - $2.19 Million
-102,510 Reduced 40.77%
148,946 $2.18 Million
Q4 2020

Feb 16, 2021

BUY
$16.56 - $18.94 $4.15 Million - $4.74 Million
250,489 Added 25903.72%
251,456 $4.37 Million
Q3 2020

Aug 05, 2021

SELL
$17.41 - $19.89 $3.62 Million - $4.13 Million
-207,758 Reduced 99.54%
967 $18,000
Q3 2020

Nov 16, 2020

BUY
$17.41 - $19.89 $3.62 Million - $4.13 Million
207,744 Added 21176.76%
208,725 $3.83 Million
Q2 2020

Aug 05, 2021

SELL
$14.43 - $19.16 $1.04 Million - $1.38 Million
-71,944 Reduced 98.65%
981 $18,000
Q2 2020

Aug 12, 2020

BUY
$14.43 - $19.16 $1.05 Million - $1.4 Million
72,925 New
72,925 $1.3 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $91.7M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.